Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma

The purpose of this study is to investigate the pharmacokinetics (PK) similarity of Bmab1700 (an intended nivolumab biosimilar), compared with United States (US)-licensed Opdivo, in participants after complete surgical removal of melanoma.

Participants needed: 120
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Biocon Biologics UK PLCUpdated: Aug 13, 2026Locations: 48
Eligibility criteria

Participants greater than or equal to (>=)18 years of age on the day of signing... [+6]

History of ocular/uveal melanoma. [+32]

Read more
Status: Not yet recruiting

Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda® as Adjuvant Monotherapy in Patients With Melanoma

The purpose of the study is to evaluate the pharmacokinetic (PK) equivalence of Bmab1800 as compared with reference product Keytruda® in a randomized, double-blind, two-arm, parallel comparative, multi-center study in patients with resected melanoma (Stage IIB, or Stage IIC, or Stage III) as an adjuvant treatment. This study also compares the safety and immunogenicity of Bmab1800 and Keytruda.

Participants needed: 138
Trial details
Phase: Phase 1Age: 18-99Biological sex: AllType: InterventionalSponsor: Biocon Biologics UK PLCUpdated: May 14, 2026
Eligibility criteria

Male or female patients aged ≥18 years (or legal adult age per local regulations... [+4]

History of ocular/uveal and mucosal melanoma. [+17]

Read more
Status: Recruiting

A Phase 1 Comparative Study to Evaluate Pharmacokinetics, Immunogenicity, Safety and Tolerability of Bmab3000 and Herceptin Hylecta® After a Single 600 mg SC Injection in Healthy Male Volunteers

This phase I study is to compare the pharmacokinetics (PK), immunogenicity, safety, and tolerability of Bmab3000 (test) and Herceptin Hylecta (reference) after a single subcutaneous (s.c.) dose in healthy male volunteers.

Participants needed: 150
Trial details
Phase: Phase 1Age: 18-65Biological sex: MaleType: InterventionalSponsor: Biocon Biologics UK PLCUpdated: Apr 8, 2026Locations: 1
Eligibility criteria

Healthy male volunteers aged between 18 to 65 years; both inclusive. [+7]

History of previous exposure to trastuzumab. [+9]

Read more